2. UroToday Home
  3. Video Lectures

CRPC with Bone Metastases Videos

PEACE-3 Trial Evaluates Radium-223 Plus Enzalutamide in Bone-Metastatic mCRPC - Enrique Gallardo Diaz
Radium-223 + Enzalutamide in mCRPC: Revisiting PEACE-3 Trial Data - Kristine Peregrino Lacuna
Bone-Protective Agents and Survival Benefits in PEACE-3 Trial Subgroup Analysis - Fred Saad
Real-World Trends in Bone Health Agent Use for Metastatic Prostate Cancer - Umang Swami
REDUSE Trial: Comparing Denosumab Dosing Intervals in mCRPC - Arnoud Templeton
Importance of Bone Protection in Prostate Cancer Treatment "Presentation" - Noel Clarke
2024 NCCN Guidelines: Managing Bone Health in Prostate Cancer Patients - Rashid Sayyid & Zachary Klaassen
2024 NCCN Guidelines: Preventing Skeletal Events in Prostate Cancer - Rashid Sayyid & Zachary Klaassen
Bone Health Management for Advanced Prostate Cancer - Fred Saad
Optimizing Multi-Disciplinary Care Teams for Radiopharmaceutical Administration - Neal Shore
The Correlation Between Alkaline Phosphatase Decline and Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer in the REASSURE Study - Nicholas James
A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore
Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff
Optimal Sequencing - Should It Include Radium Given Lutetium? - Joe O'Sullivan
Is There Still a Role for Radium-223? APCCC 2022 Presentation - Neal Shore
Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of the Bones? APCCC 2022 Presentation - Oliver Sartor
Treatment Sequencing with Radium-223 in Symptomatic Disease - Fred Saad
Identifying the Right Patients for Treatment with Radium-223 for mCRPC - Brenda Martone
Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan
A Real-World Analysis of Pain Efficacy of Radium-223 Treatment Among Patients With Metastatic Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases – the REASSURE Trial – Celestia Higano
Prospective Analysis of The Effect of Germline Mutations on Outcomes for mCRPC Patients Treated With Radium-223 (PRORADIUM) – Elena Castro
Real-World Data in Second-Line Treatment Progressing mCRPC – Oliver Sartor
Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis - Beyond the Abstract
Radium-223 Treatment for Metastatic Prostate Cancer - Ila Sethi
The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff
Patient Assessment and Treatment Strategies for mCRPC - William Oh
Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone
Ensuring Patients Have Access to Radium-223 as a Therapeutic Option: The DORA Trial - Michael Morris
The Importance of Bone-Protecting Agents When Treating mCRPC with Bone Metastatic Disease The PEACE III Trial – Silke Gillessen
The Effect of Mandated Bone Protective Agents on Fracture Risk With Longer Follow-Up (EORTC 1333 / PEACE III Trial) – Fred Saad
Changing the Mechanism of Action in The Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) - Phillip Koo
Novel Radiopharmaceuticals In Development For Treatment in Advanced Prostate Cancer - Michael Morris
Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith
Real-World Clinical Outcomes with Radium-223 in Metastatic Castration-resistant Prostate Cancer - Neal Shore
Bone Health Agents in Patients with Castrate-Resistant Prostate Cancer - Bertrand Tombal
Assessing the Aging Population and Treatment Considerations for Prostate Cancer - Joe O'Sullivan
The Risk of Dose De-intensifying Treatment, Bone Health in Prostate Cancer - Fred Saad
Radium-223 and Bone Health Agents: Lessons Learned Presentation - Oliver Sartor
Anti-Resorptive Therapy to Reduce Skeletal-Related Events Risk in Men with Bone-Metastatic CRPC Presentation - Chris Parker
Antiresorptive Therapy to Reduce SRE Risk For The Majority of Men with CRPC and Bone Metastases Presentation - Bertrand Tombal
Prevention and Treatment of Osteoporosis Presentation - Fred Saad
Contemporary Treatment of Castration-Resistant Prostate Cancer (CRPC) - Fred Saad
Sequencing Treatments in Metastatic Prostate Cancer - Evan Yu
Real World Treatment Experience with Radium-223 - Dan George
Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases
Current Management of Bone Metastatic Castrate-Resistant Prostate Cancer : Panel Discussion
Bone Health in Prostate Cancer - A Conversation with Neal Shore and Oliver Sartor
A Nuclear Radiologist’s Perspective on Bone Targeted Therapies- Phillip Koo
Decision Making When Treating Prostate Cancer - Silke Gillessen
ERA 223: Presentation Summary from ESMO 2018 - Fred Saad
The Role of Bone Health Agents in Patients with Prostate Cancer - Tia Higano
A Renewed Analysis of ERA 223 - Fred Saad
Prostate Cancer Osteomimicry in Circulating Tumor Cells in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) - Andrew Armstrong
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor
Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo